Compare TRI & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRI | NTRA |
|---|---|---|
| Founded | 1851 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 45.3B |
| IPO Year | 2002 | 2015 |
| Metric | TRI | NTRA |
|---|---|---|
| Price | $105.71 | $331.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $154.58 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $8.90 | $18.08 |
| Revenue Next Year | $7.89 | $19.65 |
| P/E Ratio | $25.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.28 | $157.43 |
| 52 Week High | $180.00 | $333.56 |
| Indicator | TRI | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 71.73 |
| Support Level | $81.19 | $187.64 |
| Resistance Level | $113.40 | N/A |
| Average True Range (ATR) | 5.45 | 10.88 |
| MACD | -0.23 | 2.40 |
| Stochastic Oscillator | 53.49 | 96.11 |
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.